Virtual Library

Start Your Search

Yusuke Kita



Author of

  • +

    P2.14 - Targeted Therapy (ID 183)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.14-05 - EGFR Mutation Status and Prognostic Impact in Patients with Surgically Resected Lung Adenocarcinoma (Now Available) (ID 700)

      10:15 - 18:15  |  Author(s): Yusuke Kita

      • Abstract
      • Slides

      Background

      Epidermal growth factor (EGFR) gene mutation status in lung adenocarcinoma has been demonstrated to reflect the therapeutic efficacy of tyrosine kinase inhibitors (TKIs). In this study, we investigated the association of EGFR mutation status with prognostic impact.

      Method

      From January 2010 to December 2018, we retrospectively reviewed 450 patients with resected lung adenocarcinomas who underwent EGFR mutation status analysis. Clinicopathological factors analyzed included age, sexgender, smoking history, serum carcinoembryonic antigen (CEA) levels, lymphatic invasion (Ly), vascular invasion (V), histological grade, malignant component, pathological stage, and EGFR mutation. Univariate and multivariate analyses of overall survival (OS) and recurrence-free survival (RFS) were conducted.

      Result

      The study group comprised 450 patients (260 men, 190 women; age range: 32–88 years; mean age: 67.6±9.9 years). The median follow-up period was 35.4 months. A total of 282 patients were smokers and 168 were nonsmokers. EGFR mutation analysis identified 186 patients with EGFR mutation and 264 patients with wild-type EGFR. Preoperative CEA was elevated in 117 patients. Ly, V, high grade, high malignant component and advanced stage were observed in 72, 73, 209, 120 and 102 patients, respectively. The 5-year OS in patients with EGFR mutation was 80.6% compared with 75.6% for those with wild-type EGFR (p=0.011). The 5-year RFS in patients with EGFR mutation status was 77.1% compared with 66.8% for patients with wild-type EGFR (p=0.036). There were no significant differences in OS and RFS between patients with exon 21 L858R, exon 19 deletion and other mutation subtypes. In addition, there was no survival difference in patients with EGFR mutation who received TKI or not after lung cancer recurrence. In multivariate analysis for OS, EGFR mutation status was an independent significant prognostic factor, as well as age, Ly, and pathological stage.

      Conclusion

      EGFR mutation status is an independent good prognostic factor in patients with resected lung adenocarcinoma regardless of TKI use. EGFR mutation subtypes did not show significant differences in prognosis.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.